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Background:  Regadenoson, a pharmacologic stress agent, is excreted primarily via the kidneys. This study examined the safety and tolerability of 
regadenoson in patients with chronic kidney disease (CKD).
Methods:  This multicenter, double-blind, randomized, placebo-controlled, parallel-group study involved men and women ≥18 years of age with 
stage 3 (glomerular filtration rate [GFR] 30-59 mL/min) or 4 (GFR 15-29 mL/min) CKD at screening and known or suspected coronary artery 
disease. Patients were randomized 2:1 to receive one 10-sec IV injection of regadenoson 0.4 mg or placebo. Adverse events (AEs) occurring within 
24 h of drug administration were collected. Estimated GFR was assessed at baseline and 24 h post-dose. The primary outcome measure was the 
frequency of serious AEs.
Results:  The study included 504 patients; 432 had stage 3 CKD (regadenoson n=287; placebo n=145) and 72 had stage 4 CKD (regadenoson 
n=47; placebo n=25). Mean age was 66.3 years and 54.8% were male. No significant differences were observed between treatment groups in 
demographics or baseline characteristics. No serious AEs or deaths were reported in the 24 h post-dose period. The overall incidence of AEs was 
higher with regadenoson than placebo (62.6% vs 21.2%; P<0.0001). The most commonly (≥5%) reported AEs by patients in the regadenoson 
group that were statistically significantly greater (P<0.0001) with regadenoson versus placebo were headache (24.9% vs 7.1%), dyspnea (19.2% vs 
0.6%), chest discomfort (14.7% vs 0.6%), nausea (14.7% vs 1.2%), flushing (12.0% vs 1.8%), and dizziness (9.6% vs 0.6%). AE profiles were similar 
between patients with stage 3 and 4 CKD for regadenoson and for placebo. There were no trends for clinically meaningful changes in estimated GFR 
(baseline to 24 h post-dose) in patients with stage 3 or 4 CKD. One placebo patient had a cardiopulmonary arrest 20 days post-dose.
Conclusions:  No unexpected AEs associated with regadenoson use were observed in patients with CKD. Regadenoson was safe and well tolerated 
in patients with stage 3 or stage 4 renal impairment. [ClinicalTrials.gov number, NCT00863707]
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